久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開發(fā)區(qū)神墩四路666號C棟

抗體:Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗體,AntibodySystem Laboratories

發(fā)表時間:2024-05-16

標題Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗體,AntibodySystem Laboratories

鏈接:https://www.antibodysystem.com/product/17748.html

名稱:Anti-Semaglutide (GLP-1 analogue) Polyclonal antibody抗體

別名:Sermaglutide, Semaglutide fandachem, Semaglutide impurity, Sermaglutide USP/EP/BP, semaglutide, Sermaglutide

貨號:PHK13901

宿主:Rabbit

適用物種:Human

免疫原:Synthesized Semaglutide (GLP-1 analogue) conjugated with Carrier protein.

存儲緩沖區(qū):PBS, pH 7.4, containing 0.05% proclin 300, 50% glycerol.

形式:Liquid

濃度:1.28 mg/ml

克?。?/b>Polyclonal

同型:IgG

應(yīng)用:WB, IHC, ELISA

CAS910463-68-2

用途范圍:僅用于科研

儲存:Use a manual defrost freezer and avoid repeated freeze thaw cycles.Store at 4°C for frequent use.Store at -20 to -80 °C for twelve months from the date of receipt.

產(chǎn)品購買聯(lián)系方式:027-65279366 /18162686757

郵箱:biolab-reagents@atagenix.com

QQ2663991332

 

參考文獻:

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. PMID: 26308095

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. PMID: 33068776

GLP-1 receptor agonists and cardiovascular outcome trials: An update. PMID: 30528435

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. PMID: 38286487

Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. PMID: 34911560

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). PMID: 30944040

Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. PMID: 34015974

Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. PMID: 32910487

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. PMID: 38316982

Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. PMID: 38079178

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. PMID: 32987188

The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. PMID: 37684186

Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist. PMID: 29915923

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. PMID: 37952217

Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. PMID: 37796527

Semaglutide (Ozempic) for weight loss. PMID: 33830968

Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. PMID: 31612934

Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report. PMID: 37280458

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? PMID: 30156747

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. PMID: 35838946

Liraglutide and obesity: a review of the data so far. PMID: 25848222

Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure. PMID: 37409733

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. PMID: 28266779

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). PMID: 38087976

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity. PMID: 38060218

GLP-1 as a target for therapeutic intervention. PMID: 27591964

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. PMID: 37952131

Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. PMID: 31436480

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. PMID: 17098089

GLP-1 analogue therapy for obesity in people from Asia. PMID: 38330985

The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia. PMID: 35080714

Efficacy and safety of semaglutide for weight management: evidence from the STEP program. PMID: 36691309

The Future of the GLP-1 Receptor Agonists. PMID: 30903797

聯(lián)系方式
手機:18162686757
微信掃一掃
米林县| 栖霞市| 牡丹江市| 精河县| 达州市| 岗巴县| 浦城县| 江西省| 乌恰县| 乌鲁木齐县| 永宁县| 湖北省| 汝州市| 古丈县| 开平市| 邓州市| 巴彦淖尔市| 谷城县| 两当县| 定兴县| 竹溪县| 喀喇沁旗| 涟源市| 乐都县| 湟源县| 延庆县| 民乐县| 府谷县| 定襄县| 榆社县| 大方县| 商水县| 治县。| 富锦市| 格尔木市| 新营市| 治多县| 河北省| 察隅县| 湘潭市| 同江市|